Julie Collins

发表

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

E. Stringer-Reasor, S. Tolaney, C. Jochems, 2024, Nature communications.

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

E. Stringer-Reasor, S. Tolaney, C. Jochems, 2023, medRxiv.